BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Update
by Scott Moore · The Cerbat GemBriaCell Therapeutics Corp. (NASDAQ:BCTXW – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 14,100 shares, an increase of 422.2% from the September 30th total of 2,700 shares. Based on an average trading volume of 106,100 shares, the short-interest ratio is currently 0.1 days.
BriaCell Therapeutics Price Performance
NASDAQ:BCTXW opened at $0.33 on Friday. BriaCell Therapeutics has a 1 year low of $0.11 and a 1 year high of $2.60. The stock has a 50-day moving average price of $0.29 and a two-hundred day moving average price of $0.41.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
Read More
- Five stocks we like better than BriaCell Therapeutics
- How to Invest in Blue Chip Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Warren Buffett Stocks to Buy Now
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- P/E Ratio Calculation: How to Assess Stocks
- MarketBeat Week in Review – 10/21- 10/25